Sequencing, Combination, and Reassessment

Prev
 1 / 21 
Next
Prev
 1 / 21 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • explain why CAD management is dynamic rather than linear
  • distinguish control, modification, and observation as goal-driven strategies
  • recognize when sequencing or overlap is appropriate
  • identify triggers that warrant reassessment
  • understand when de-escalation is appropriate
  • apply longitudinal reasoning to clinical decisions

What is the most accurate description of treatment strategy in CAD?

a
A fixed therapeutic ladder based on diagnosis
CAD does not follow a single ladder.
b
A sequence determined primarily by guideline algorithms
Guidelines inform options but do not determine sequence.
c
A dynamic process aligned with disease activity, mechanism, and goals
Strategy must match biology and priorities at each moment.
d
A stepwise escalation until hemoglobin normalizes
Treating numbers alone is not the goal.

Which clinical situation most strongly favors complement-directed therapy as initial strategy?

a
Stable mild anemia without symptoms
Observation may be sufficient.
b
Acute symptomatic hemolysis
Complement inhibition provides rapid control.
c
Long-term remission as primary goal
That goal favors modification strategies.
d
Preference for finite therapy
Complement inhibition is typically continuous.

Why is clone-directed therapy often delayed until disease is stable?

a
It is ineffective in CAD
It can be effective.
b
It only works in severe anemia
Severity alone does not determine use.
c
It cannot be combined with other therapies
Combination strategies may be intentional.
d
Its benefit is delayed relative to complement inhibition
Response occurs more slowly than control-oriented therapy.

Which therapy is generally ineffective in CAD because of disease mechanism?

a
Corticosteroids
Corticosteroids target IgG-mediated and splenic clearance pathways, which are not dominant in IgM-mediated complement-driven CAD.
b
Complement inhibition
Targets central effector pathway.
c
Rituximab-based therapy
Targets pathogenic clone.
d
Cold avoidance
Supportive strategies can be effective.

What is the most common conceptual error in CAD treatment selection?

a
Using combination therapy
Combination therapy may be appropriate.
b
Choosing therapy before defining the clinical goal
Strategy must follow goal, not precede it.
c
Monitoring hemolysis markers
Monitoring is essential.
d
Discussing patient preferences
Preferences are part of expert care.

Which situation most clearly warrants reassessment of current strategy?

a
Stable hemoglobin and stable symptoms
Stability supports continuation, though reassessment remains routine.
b
Persistent fatigue despite stable labs
Symptoms may signal mismatch between strategy and lived experience.
c
Seasonal cold exposure without clinical change
Environmental exposure alone does not require strategy change if disease metrics are stable.
d
Stable disease during therapy
Stability argues for continuation.

When is overlap of control and modification strategies most justified?

a
Newly diagnosed CAD
New diagnosis alone does not define the clinical goal that would justify overlapping strategies.
b
Mild asymptomatic disease
Combination increases risk unnecessarily.
c
Acute hemolysis with long-term remission goal
Immediate control plus long-term modification addresses different time horizons.
d
Patient request for aggressive treatment
Preference alone does not justify escalation.

Which statement best describes reassessment in CAD care?

a
It signals initial treatment failure
Reassessment is expected, not failure.
b
It reflects diagnostic uncertainty
Diagnosis may be secure.
c
It is only necessary after relapse
Waiting for relapse risks harm.
d
It is a routine therapeutic step in chronic disease
Longitudinal diseases require periodic realignment.

A patient observed for 2 years develops increasing transfusion needs and worsening cold-induced pain. What does this change most clearly indicate?

a
Observation was incorrect from the start
Observation may have been appropriate earlier.
b
A gradual evolution in disease expression requiring reassessment
The key signal is changing trajectory, which prompts reassessment of strategy.
c
The disease has suddenly transformed biologically
Abrupt transformation is not required to justify reassessment.
d
Treatment is now mandatory regardless of preference
Decisions still require judgment.

Which principle best captures expert longitudinal management?

a
Treat aggressively early to prevent complications
Aggression is not always appropriate.
b
Maintain initial therapy unless relapse occurs
Static therapy ignores change.
c
Adjust therapy whenever biology or priorities change
Strategy must track evolving context.
d
Follow a standard sequence for all patients
No single sequence fits all patients.

A patient achieves stable hemoglobin on complement inhibition and asks whether therapy can be stopped. What is the most accurate response?

a
Complement inhibition can be stopped once hemoglobin stabilizes
b
Control usually persists only while therapy continues
c
All CAD therapies require indefinite treatment
d
Discontinuation should be attempted annually

A patient on complement inhibition develops slowly rising transfusion requirements over months, yet therapy is unchanged. This most likely represents:

a
Appropriate observation
b
Therapeutic inertia
c
Permanent treatment failure
d
Expected plateau

A patient begins clone-directed therapy while continuing complement inhibition to maintain stability during induction. This approach is best described as:

a
Sequential logic with intentional overlap
b
Redundant therapy
c
True combination therapy
d
Diagnostic uncertainty

Sort each feature into the correct category:

Accepts delayed benefit
Requires ongoing therapy
May allow treatment-free intervals
Targets pathogenic clone
Bridges unstable periods
Prioritizes speed
Cold avoidance
Control
Modification
Supportive

Match each concept to its clinical implication:

Observation
Complement inhibition
Clone-directed therapy
Treatment risk exceeds burden
Rapid stabilization
Durability potential
Correct! Sorry, Incorrect.

Closing Note

Cold agglutinin disease is not managed by selecting the right drug once.
It is managed by repeatedly asking the right question.

Expert care lies not in choosing therapy, but in recognizing when the clinical question has changed.

Prev
 1 / 21 
Next